Riverwater Partners LLC Sells 8,174 Shares of LeMaitre Vascular, Inc. $LMAT

Riverwater Partners LLC cut its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 28.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,001 shares of the medical instruments supplier’s stock after selling 8,174 shares during the quarter. Riverwater Partners LLC owned about 0.09% of LeMaitre Vascular worth $1,838,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in LMAT. Kornitzer Capital Management Inc. KS increased its holdings in shares of LeMaitre Vascular by 18.0% in the third quarter. Kornitzer Capital Management Inc. KS now owns 13,090 shares of the medical instruments supplier’s stock valued at $1,146,000 after purchasing an additional 2,000 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in LeMaitre Vascular by 16.1% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 3,133 shares of the medical instruments supplier’s stock valued at $274,000 after buying an additional 434 shares during the last quarter. Mutual of America Capital Management LLC raised its holdings in LeMaitre Vascular by 27.5% in the 3rd quarter. Mutual of America Capital Management LLC now owns 48,448 shares of the medical instruments supplier’s stock valued at $4,240,000 after acquiring an additional 10,451 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in LeMaitre Vascular during the third quarter worth approximately $853,000. Finally, Palisades Investment Partners LLC bought a new stake in shares of LeMaitre Vascular during the third quarter worth approximately $303,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on LMAT shares. Barrington Research reaffirmed an “outperform” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, October 15th. Zacks Research lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Wells Fargo & Company decreased their target price on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research report on Friday, November 7th. Roth Mkm restated a “buy” rating and set a $108.00 price objective on shares of LeMaitre Vascular in a research note on Wednesday, November 5th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $100.20.

LeMaitre Vascular Stock Up 1.3%

Shares of NASDAQ LMAT opened at $85.28 on Tuesday. The stock has a 50-day moving average price of $84.31 and a two-hundred day moving average price of $87.49. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $105.55. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44. The company has a market cap of $1.94 billion, a price-to-earnings ratio of 36.76, a PEG ratio of 1.87 and a beta of 0.68.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.05. LeMaitre Vascular had a net margin of 22.14% and a return on equity of 14.06%. The business had revenue of $61.05 million during the quarter, compared to analysts’ expectations of $62.18 million. During the same period in the prior year, the company earned $0.49 EPS. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. As a group, analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.